Resources for newly funded immune checkpoint inhibitors for non-small cell lung cancer
Immune checkpoint inhibitors for non-small cell lung cancer
From 1 April 2023, Pharmac funded two new treatments for non-small cell lung cancer. We widened access to pembrolizumab (Keytruda) as a first-line treatment and newly funded atezolizumab (Tecentriq) as a second line treatment.
We asked the experts to develop resources to support healthcare professionals and people being treated with these medicines.
Resource for health care professionals
He Ako Hiringa have developed a comprehensive guide to what to look for with lung cancer through to important side effects to watch out for.
Resource for people being treated
Healthify has developed a plain language guide for what people need to know about taking an immune checkpoint inhibitor for non-small cell lung cancer. They also discuss pembrolizumab and atezolizumab in greater detail, so you know what to expect.
Who to contact
If you have any questions about the funding of these medicines, email email@example.com